Former Wyeth executive joins Ricerca Biosciences

Michael Placke takes position of senior vice president and general manager

Michael Placke will join Ricerca Biosciences as senior vice president and general manager at the CRO’s Concord, Ohio, facility on 24 May.

He will be responsible for the operations and business performance of Ricerca’s Concord site and will be working with the executive team participating in the global integration of Concord, Ohio, based services to the recently acquired DSA services in Lyon, France, and the pharmacology/DMPK services in Bothell, Washington and Taipei, Taiwan.

Prior to this position, Placke was vice president, drug safety, at Wyeth Research (now Pfizer) in Chazy, New York, where he was responsible for leading all non-clinical drug safety evaluations and support of Wyeth’s drug development portfolio from candidate selections through post-marketing assessment. Before joining Wyeth, he was with Battelle Pharma, in Columbus, Ohio, where he was vice president, pharmaceutical development, and chief scientist from 1999 to 2003.

You may also like

Research & Development

Celerion and Ricerca Biosciences to provide integrated service for biosimilars

Will test viability of a potential biosimilar early in the process
Research & Development

Ricerca announces similarity analysis service

Foresight allows compound assay results to be compared against pharmacologically active compounds
Research & Development

Ricerca and LSP agree business development collaboration

Ricerca will expand its presence in Japan, Korea and overall Asian market
Regulatory

Ricerca completes purchase of MDS Pharma businesses

The acquisition gives Ohio-based Ricerca more capacity and capabilities.
Research & Development

MDS to sell early stage business to Ricerca

MDS Pharma Services is to sell its remaining discovery and pre-clinical operations to Ohio-based Ricerca Biosciences for US$45m.
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

The path to commercial allogeneic iPSC therapies

The cell therapy sector is currently shifting from patient-specific autologous treatments toward off-the-shelf allogeneic cell therapies. Although this transition is helping to democratise access to treatments, it introduces several challenges in terms of controlling complex biology at a commercial scale
Research & Development

The IND advantage: why early derisking is a strategic imperative for complex biologics

As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Subscribe now